Secukinumab 300mg at week 52 in ankylosing spondylitis patients (who did not achieve inactive disease with SEC 150mg at week 16) experienced similar clinical response and safety profile regardless of dose escalation. #EULAR2022 @RheumNow #ABSTOP0023 https://t.co/7LeZMMWeRC